Silencing endogenous EGFR4 expression in ER+ MCF7 and T47D breast tumor cell lines reduces anchorage-independent proliferation stimulated by an EGFR4 ligand such as neuregulin-2beta [110, 126]. This evidence concerns the gene ESR1 and breast neoplasm.